Acute Leukemia French Association
20
5
6
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
4 terminated/withdrawn out of 20 trials
71.4%
-15.1% vs industry average
40%
8 trials in Phase 3/4
0%
0 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Role: collaborator
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML
Role: collaborator
OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia
Role: collaborator
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
Role: lead
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
Role: lead
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Role: collaborator
Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm
Role: collaborator
Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine
Role: collaborator
A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE
Role: collaborator
Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Role: collaborator
HCT Versus CT in Elderly AML
Role: collaborator
Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
Role: collaborator
ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Role: lead
DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML
Role: lead
Timed-Sequential Induction in CBF-AML
Role: collaborator
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Role: lead
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
Role: collaborator
Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2
Role: lead
Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML)
Role: lead
A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
Role: lead
All 20 trials loaded